Facilitation of latent inhibition by the atypical antipsychotic risperidone

Pharmacology Biochemistry and Behavior

Volumn 68, Issue 3, 2001, Pages 503-506

  Alves, Cilene R R ^a   Teresa A Silva, M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal models; Atypical antipsychotics; Latent inhibition; LI; Risperidone; Schizophrenia

Indexed keywords

DRUG VEHICLE; NEUROLEPTIC AGENT; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRINKING; DRUG ACTIVITY; DRUG EFFICACY; FACILITATION; LATENT INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STIMULUS RESPONSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, WISTAR; RISPERIDONE; STARTLE REACTION;

EID: 0035019247     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(01)00475-0     Document Type: Article

References (30)

1. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Oilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics 9th ed. New York: McGraw-Hill, 1996. pp. 399-430.
2. Baruch I, Hemsley DR, Jeffrey AG. Latent inhibition and "psychotic proneness" in normal subjects. Pers Individ Differ 1988a;9:777-83.
3. Baruch I, Hemsley DR, Gray JA. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 1988b;176:598-606.
4. Buckley PF, Meltzer HY. Treatment of schizophrenia. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. London: American Psychiatric Press, 1995. pp. 615-39.
5. Chouinard G, Janes B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
6. Dunn LA, Atwater GE, Kilts CD. Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology 1993;112:315-23.
7. Feldon J, Weiner I. The latent inhibition model of schizophrenic attention disorder haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 1991;29:635-46.
8. Gosselin G, Oberling P, Di Scala G. Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behav Pharmacol 1996;7:820-6.
9. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA. Abolition of latent inhibition by a single 5 mg dose of D-amphetamine in man. Psychopharmacology 1992;107:425-30.
10. Hitchcock JM, Lister S, Fischer TR, Wettstein JG. Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol. Behav Brain Res 1997;88:43-9.
11. Killcross AS, Dickinson A, Robbins TW. Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology 1994;115:196-205.
12. Leysen JE, Janssen PMF, Megens AHP, Schotte A. A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55:5-12.
13. Lubow RE. Latent inhibition. Psychol Bull 1973;79:398-407.
14. Lubow RE, Weiner I, Feldon J. An animal model of attention. In: Spiegelstein MY, Levy A, editors. Behavioral models and analysis of drug action. Amsterdam: Elsevier, 1982. pp. 89-107.
15. Mackintosh NJ. A theory of attention: variations in the associability of stimuli with reinforcement. Psychol Rev 1975;82:276-98.
16. Moran PM, Fischer JM, Hitchcock JM, Moser PC. Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 1996;7:42-8.
17. Moser PC, Moran PM, Frank RA, Kehne JH. Reversal of amphetamine-induced behaviors by MDL 100,907, a selective 5-HT2A antagonist. Behav Brain Res 1996;73:163-7.
18. Peters SL, Joseph MH. Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioning rather than pre-exposure. Behav Pharmacol 1993;4:183-6.
19. Schatzberg AF, Nemeroff CB. Textbook of psychopharmacology Washington: American Psychiatric Press, 1995.
20. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
21. Shadach E, Feldon J, Weiner I. Clozapine-induced potentiation of latent inhibition is due to its action in conditioning stage: implications for the mechanism of action of antipsychotic drugs. Int J Neuropsychopharmacol 1999;2:283-91.
22. Shadach E, Gaisler I, Schiller D, Weiner I. The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology 2000;23:151-61.
23. Trimble KM, Bell R, King DJ. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. Pharmacol, Biochem Behav 1997;56:809-16.
24. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology 1994;114:657-64.
25. Weiner I. Neural substrates of latent inhibition: the switching model. Psychol Bull 1990;108:442-61.
26. Weiner I, Feldon J. Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 1987;91:248-53.
27. Weiner I, Feldon J. The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 1997;88:11-25.
28. Weiner I, Lubow RE, Feldon J. Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol, Biochem Behav 1988;30:871-8.
29. Weiner I, Shadach E, Barkai R, Feldon J. Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology 1997;16:42-50.
30. Williams JH, Wellman NA, Geaney DP, Feldon J, Cowen PJ, Rawlins JNP. Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology 1997;133:262-8.